TruScreen2 Sales to China commence following CFDA Approval

NZX and Media Release 21 December, 2017 NZX Limited WELLINGTON TruScreen2 Sales to China commence following CFDA Approval Cervical cancer screening technology company, TruScreen Limited (NZAX: TRU) advises that, following on from receipt of China Food and Drug Administration (CFDA) approval for its new TruScreen2 device, as announced on 4 December 2017, it has now received an initial payment of NZ$188,000 against initial orders from its Chinese distributor. TruScreen chair, Robert Hunter, said "The establishment of a market for TruScreen2 in China has been a major focus for the company and, as previously announced, there has been strong interest in TruScreen2 pending CFDA approval. The company is now producing consoles at its maximum capacity to meet current and anticipated orders from China which is our largest target market." ENDS For more information visit www.truscreen.com or contact: Martin Dillon TruScreen Chief Executive Officer Email: martindillon@truscreen.com Media Liaison Jackie Ellis Email: jackie@ellisandco.co.nz Phone: +64 27 246 2505 About TruScreen: TruScreen's real time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissue. A sophisticated proprietary algorithm framework distinguishes between normal and abnormal (cancerous and precancerous) tissue to identify precancerous change, or cervical intraepithelial neoplasia (CIN). A Single Use Sensor (SUS) is used for each patient to protect against cross-infection. End CA:00312270 For:TRU Type:GENERAL Time:2017-12-21 08:30:53